Roles of opioid receptor subtypes on the antinociceptive effect of intrathecal sildenafil in the formalin test of rats

[1]  W. Kim,et al.  Additive Antinociception between Intrathecal Sildenafil and Morphine in the Rat Formalin Test , 2008, Journal of Korean medical science.

[2]  A. Hidalgo,et al.  Involvement of nitric oxide in the inhibition of bone cancer-induced hyperalgesia through the activation of peripheral opioid receptors in mice , 2007, Neuropharmacology.

[3]  R. Ribeiro,et al.  Role of NO/cGMP/KATP pathway in antinociceptive effect of sildenafil in zymosan writhing response in mice , 2007, Inflammation Research.

[4]  C. Stief,et al.  Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. , 2006, European urology.

[5]  F. Pérez-Severiano,et al.  Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats. , 2005, European journal of pharmacology.

[6]  P. Pagliaro.  Differential biological effects of products of nitric oxide (NO) synthase: it is not enough to say NO. , 2003, Life sciences.

[7]  S. Snyder,et al.  Historical review: Opioid receptors. , 2003, Trends in pharmacological sciences.

[8]  C. S. Patil,et al.  Sildenafil-induced peripheral analgesia and activation of the nitric oxide–cyclic GMP pathway , 2001, Brain Research.

[9]  W. A. Prado,et al.  The dual effect of a nitric oxide donor in nociception , 2001, Brain Research.

[10]  P. Portoghese,et al.  5'-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist , 2000 .

[11]  V. Arshavsky,et al.  cGMP signal termination. , 1996, Biochemical Society transactions.

[12]  J C Gingell,et al.  Sildenafil, a novel effective oral therapy for male erectile dysfunction. , 1996, British journal of urology.

[13]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[14]  S. Ferreira,et al.  The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. , 1991, European journal of pharmacology.

[15]  S. Ferreira,et al.  Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. , 1990, European journal of pharmacology.

[16]  P. Portoghese,et al.  Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. , 1990, Journal of medicinal chemistry.

[17]  S. Ferreira,et al.  I - Prostaglandin hyperalgesia, a cAMP/Ca2+ dependent process. , 1979, Prostaglandins.

[18]  T. Deguchi.  Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. , 1977, The Journal of biological chemistry.

[19]  T. Yaksh,et al.  Chronic catheterization of the spinal subarachnoid space , 1976, Physiology & Behavior.

[20]  C. S. Patil,et al.  Peripheral and central activation of nitric oxide-cyclic GMP pathway by sildenafil , 2006, InflammoPharmacology.

[21]  K. Chaturvedi,et al.  Structure and regulation of opioid receptors. , 2000, Biopolymers.

[22]  V. Hruby,et al.  [3H]-[H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2] ([3H]CTOP), a potent and highly selective peptide for mu opioid receptors in rat brain. , 1989, The Journal of pharmacology and experimental therapeutics.